HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early liver transplantation for severe alcoholic hepatitis.

AbstractBACKGROUND:
A 6-month abstinence from alcohol is usually required before patients with severe alcoholic hepatitis are considered for liver transplantation. Patients whose hepatitis is not responding to medical therapy have a 6-month survival rate of approximately 30%. Since most alcoholic hepatitis deaths occur within 2 months, early liver transplantation is attractive but controversial.
METHODS:
We selected patients from seven centers for early liver transplantation. The patients had no prior episodes of alcoholic hepatitis and had scores of 0.45 or higher according to the Lille model (which calculates scores ranging from 0 to 1, with a score ≥ 0.45 indicating nonresponse to medical therapy and an increased risk of death in the absence of transplantation) or rapid worsening of liver function despite medical therapy. Selected patients also had supportive family members, no severe coexisting conditions, and a commitment to alcohol abstinence. Survival was compared between patients who underwent early liver transplantation and matched patients who did not.
RESULTS:
In all, 26 patients with severe alcoholic hepatitis at high risk of death (median Lille score, 0.88) were selected and placed on the list for a liver transplant within a median of 13 days after nonresponse to medical therapy. Fewer than 2% of patients admitted for an episode of severe alcoholic hepatitis were selected. The centers used 2.9% of available grafts for this indication. The cumulative 6-month survival rate (±SE) was higher among patients who received early transplantation than among those who did not (77 ± 8% vs. 23 ± 8%, P<0.001). This benefit of early transplantation was maintained through 2 years of follow-up (hazard ratio, 6.08; P = 0.004). Three patients resumed drinking alcohol: one at 720 days, one at 740 days, and one at 1140 days after transplantation.
CONCLUSIONS:
Early liver transplantation can improve survival in patients with a first episode of severe alcoholic hepatitis not responding to medical therapy. (Funded by Société Nationale Française de Gastroentérologie.).
AuthorsPhilippe Mathurin, Christophe Moreno, Didier Samuel, Jérôme Dumortier, Julia Salleron, François Durand, Hélène Castel, Alain Duhamel, Georges-Philippe Pageaux, Vincent Leroy, Sébastien Dharancy, Alexandre Louvet, Emmanuel Boleslawski, Valerio Lucidi, Thierry Gustot, Claire Francoz, Christian Letoublon, Denis Castaing, Jacques Belghiti, Vincent Donckier, François-René Pruvot, Jean-Charles Duclos-Vallée
JournalThe New England journal of medicine (N Engl J Med) Vol. 365 Issue 19 Pg. 1790-800 (Nov 10 2011) ISSN: 1533-4406 [Electronic] United States
PMID22070476 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Glucocorticoids
Topics
  • Adult
  • Alcoholism
  • Case-Control Studies
  • Female
  • Follow-Up Studies
  • Glucocorticoids (therapeutic use)
  • Hepatitis, Alcoholic (drug therapy, mortality, surgery)
  • Humans
  • Kaplan-Meier Estimate
  • Liver Transplantation
  • Male
  • Middle Aged
  • Patient Selection
  • Proportional Hazards Models
  • Recurrence
  • Survival Rate
  • Temperance
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: